Loader

What Do Global Pharma Companies Get Wrong When Entering India?

Blog

Introduction

India remains one of the most attractive healthcare markets in the world. Its size, growing healthcare needs, expanding infrastructure and increasing access to care make it an important market for many global pharmaceutical and healthcare companies.

Over the course of my career, I have had the opportunity to work on the launch of several major global healthcare brands in India. Through those experiences, I have observed that the opportunities in India are often well understood. The challenges, however, are not always where companies expect them to be.

Many discussions around entering India focus on regulations, pricing, partnerships or market size. These are all important considerations. Yet, in my experience, some of the most significant mistakes happen much earlier, when companies are trying to understand the market, estimate the opportunity and build expectations for how quickly that opportunity can be converted into business success.

The observations in this article are not intended to be a comprehensive list of market-entry challenges. Rather, they reflect a few recurring patterns I have seen firsthand while working on launches and growth plans for global healthcare brands in India.

Here are four mistakes that, in my view, global pharmaceutical companies are most likely to make when entering the Indian market.

Mistake 1: Treating India as One Market

(Understanding the Market)

India is not one market. It is large, complex and incredibly diverse. Even after living here for decades, I continue to be surprised by the diversity of its people, languages and cultures.

I remember trying to explain market segments to my global and Asia-Pacific colleagues while working on a launch plan. It was nearly impossible to explain the extent of the variation.

India changes every 100 metres in a metro such as Mumbai or Delhi. Purchasing power, the type of residence people live in and their livelihoods can vary significantly. Or perhaps it is more accurate to say that even within a small geographical area, you find a mix of all these different profiles.

There are, in effect, many Indias within India.

However, while it is important to recognise this diversity, it is equally important not to get lost in it. You cannot address every India when you are trying to market or sell a product or offering. You have to identify the right groups of people, customer segments and markets where you are most likely to succeed.

Understanding India, therefore, is not just about recognising that it is a diverse market. It is about identifying which parts of that market are relevant to your business and where you should focus your efforts.

This is an important decision to get right at the outset.

Mistake 2: Confusing Population Size with Addressable Opportunity

(Sizing the Opportunity)

Looking at India's population of approximately 1.4 billion as the potential market for a product would be a gross overestimation. Most companies understand this. What is sometimes missed is the extent to which the addressable market needs to be narrowed down further.

A large proportion of India's population may not have access to many of the products offered by global healthcare companies. Factors such as affordability and the rural-urban divide are obvious starting points, but the assessment needs to go much deeper.

The relevant patient population, ability to pay, availability of healthcare facilities and access to appropriate healthcare professionals all influence how much of the potential market can actually be reached.

But there is another dimension to this.

The market that a company can address at the time of entry need not remain the same over the years. If a product addresses an unmet healthcare need and establishes itself successfully, there is a possibility of expanding access to other sections of the population over time.

This is an important consideration when assessing the Indian opportunity. Even a relatively small initial target market can represent a sizeable business in absolute terms. And the opportunity could grow considerably as access expands.

The challenge is that it is difficult to predict when, and how quickly, this deeper penetration will happen. It depends on several factors, including the nature of the product, the healthcare infrastructure, affordability and the development of the market itself.

Therefore, market entry plans need to look beyond the initial addressable market. They need to consider how the opportunity could evolve over time, and build business projections around different stages of market development.

This is where even well-researched market estimates and business plans can go awry.

Mistake 3: Overestimating the Speed of Adoption

(Forecasting Growth)

This is closely linked to estimating the size of the opportunity, but it is a different challenge.

Knowing how much of the market you can potentially address is one thing. Estimating how quickly you can establish your presence and grow within it is quite another.

Launching a product is challenging in any market. For a company entering India for the first time, however, there can be a particularly steep learning curve.

India itself is evolving rapidly, as are its healthcare systems. This can create unexpected hurdles and delays at various stages, even before the product is commercially launched.

And once the product is launched, the company enters a busy and fragmented healthcare market with very different access points and dynamics.

Consider the range: from a solo doctor's clinic in a far-flung suburb of Chennai, to a modern hospital with world-class facilities a short distance away. A few hundred miles away, patients may be accessing treatment through a Primary Health Centre (PHC), with an entirely different set of dynamics.

All of this is served by busy healthcare professionals, often managing very large patient loads.

For a company new to the Indian market, understanding these different environments, how they function and how quickly a product can gain acceptance is not easy.

From personal experience, while launching a new franchise for an MNC in India, despite conducting thorough market research and testing our product concepts extensively with various stakeholders, I realised that what happens after launch can never be predicted with 100% accuracy. There are simply too many moving parts. In such situations, it helps to develop alternative scenarios and think through potential responses in advance. The stakes are often high, and having contingency plans has proved invaluable to me in the past.

 

Consequently, there is a real risk of getting business aspirations and growth projections wrong — either aiming too big or too small.

The challenge is not just estimating the initial business. It is also anticipating how the business will develop, what hurdles it may encounter and how quickly different parts of the market may adopt the product.

A realistic growth plan needs to account for this uncertainty rather than assume that market potential will translate into business at a predictable pace.

Mistake 4: Choosing the Wrong Commercial Model or Local Partner

(Executing Successfully)

The choice of commercial model and, where relevant, a local partner is another important decision for a global pharmaceutical company entering India.

The right approach will depend on the opportunity being pursued, the customer segments being targeted, the company's longer-term ambitions and the capabilities it can bring to the market.

A company looking to address a relatively focused market will have very different requirements from one planning to build a much larger presence across multiple therapies or customer segments.

Similarly, the capabilities required to establish an initial presence may not be the same as those needed to expand the business over the next three to five years.

This makes the choice of commercial model important. Should the company establish its own presence, work through a local partner, or consider a combination of the two? There is no single answer that works for every situation.

Where a partner is involved, the decision should go beyond immediate market reach. The partner's capabilities, market understanding, ability to execute and alignment with the company's longer-term objectives also need to be considered.

Getting this decision wrong can affect not just the success of the initial launch, but also a company's ability to scale and realise the larger opportunity in India over the long term.

Conclusion

India remains one of the most attractive healthcare markets in the world. Yet many global companies make the same mistake. They see the scale first and only later discover the complexity.

The mistake is not overestimating India's potential. The mistake is assuming that the full opportunity can be understood, forecast and captured from the outset.

Success in India rarely comes from trying to address the entire opportunity from day one. More often, it comes from identifying the right patient groups, healthcare professionals, institutions and geographies where a company can establish a strong foothold before expanding further.

Looking back at the four mistakes discussed in this article, a common theme emerges. India's scale is relatively easy to see. Understanding where meaningful access exists is more difficult. Predicting how quickly adoption will follow is harder still.

The companies that succeed are usually those that recognize the difference early, build realistic expectations, and develop their strategy around where they can win first before expanding their reach over time.

 ------------------------------------------------------------------------------------------------------------------------

At Aovantage, we combine deep healthcare experience, a strong understanding of the Indian market and hands-on experience in launching global healthcare brands in India. We help global companies navigate market entry, develop the right launch strategy and build sustainable business growth.